1,237 results match your criteria Blood Transfusion[Journal]


Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".

Blood Transfus 2020 05;18(3):239-240

"IRCCS Ca' Granda Maggiore" Hospital Foundation, "Angelo Bianchi Bonomi" Haemophilia and Thrombosis Center and "Fondazione Luigi Villa", Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0116-20DOI Listing

Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.

Blood Transfus 2020 05;18(3):237-238

Intensive Cardiac Care Unit and "De Gasperis" Cardio Center, "ASST Grande Ospedale Metropolitano Niguarda", Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0109-20DOI Listing

A multimodal practical approach in a Transfusion Medicine Centre to face the COVID-19 outbreak.

Blood Transfus 2020 05;18(3):235-236

Blood Bank, Immunohaematology and Transfusion Medicine Center; "A.O.U. Città della Salute e della Scienza di Torino", Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0084-20DOI Listing

Use of eye drops obtained from homologous blood source in the time of COVID-19: is there cause for ophthalmological concern?

Blood Transfus 2020 05;18(3):233-234

Ophthalmology Unit, "S. Orsola-Malpighi" Teaching Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0090-20DOI Listing

Blood supply and transfusion support in southern Italy: findings during the first four weeks of the SARS-CoV-2 pandemic.

Blood Transfus 2020 May;18(3):230-232

Immunohematology and Transfusion Medicine Service, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, University of Bari "Aldo Moro", Bari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0107-20DOI Listing

Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.

Blood Transfus 2020 05;18(3):163-166

Transfusional Medicine Unit, University-Hospital Policlinico, Bari, Italy.

Passive immunotherapy with plasma derived from convalescent patients recovering from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that blood establishments are ready to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution, and control of product use. This Position paper aims to give recommendations on the biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0124-20DOI Listing

The effect of donor's characteristics on plasmapheresis products: insights for a personalised approach.

Blood Transfus 2020 May 9;18(3):170-175. Epub 2020 Apr 9.

Transfusion Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Background: Anticoagulant concentration in plasma units is extremely variable. Understanding the underlying causes of this variability could help personalise plasmapheresis procedures in order to optimise the risk-benefit ratio. We studied the association between anticoagulant solution A (usually ACD-A, Citrate Dextrose Solution A) volume in plasma units and donor characteristics to build a model to determine the needed weight of the final plasma unit to have an 80% probability of reaching 600 mL net plasma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0247-19DOI Listing

COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).

Blood Transfus 2020 May 8;18(3):167-169. Epub 2020 Apr 8.

IRCCS "Ca' Granda Maggiore" Hospital Foundation, "Angelo Bianchi Bonomi" Haemophilia and Thrombosis Center and "Fondazione Luigi Villa", Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0083-20DOI Listing

Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: from product development to clinical application.

Blood Transfus 2020 May 3;18(3):208-216. Epub 2020 Apr 3.

"Banc de Sang i Teixits", Barcelona, Spain.

Background: There are many advantages to using cord blood (CB) as a source of therapeutic platelet and plasma derivatives for regenerative medicine. These include availability, universal use, young donor source, and virally safe biological material, rich in tissue regenerative factors.

Materials And Methods: We aimed to validate a bioprocess design for the production of cord blood-derived platelet concentrates (CBPC) in a public Cord Blood Bank (CBB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0305-19DOI Listing

On the relevance of preoperative haemoglobin optimisation within a Patient Blood Management programme for elective hip arthroplasty surgery.

Blood Transfus 2020 May 10;18(3):182-190. Epub 2020 Apr 10.

Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, University of Málaga, Málaga, Spain.

Background: Preoperative anaemia is highly prevalent among patients scheduled for total hip arthroplasty (THA), and is the main risk factor for perioperative red blood cell transfusion (RBCT). This retrospective cohort study aimed at assessing whether preoperative haemoglobin (Hb) optimisation reduced RBCT rates and improved outcome in this patient population.

Materials And Methods: All patients entered a Patient Blood Management (PBM) programme consisting of in-hospital erythropoiesis stimulation, tranexamic acid administration, and a restrictive RBCT policy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0057-20DOI Listing

Two novel mutations p. L319V and p. L91P in ABO glycosyltransferases lead to A and B phenotypes.

Blood Transfus 2020 Apr 3. Epub 2020 Apr 3.

Blood Transfusion Department, "Ruijin" Hospital, Medical School of Shanghai "Jiao Tong" University, Shanghai, China.

Background: Mutations of the ABO gene may cause the dysfunction of ABO glycosyltransferase (GT) that can result in weak ABO phenotypes. Here, we identified two novel weak ABO subgroup alleles and explored their mechanisms that caused A and B phenotypes.

Materials And Methods: The ABO phenotyping and genotyping were performed by serological studies and direct DNA sequencing of the ABO gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0008-20DOI Listing

Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.

Blood Transfus 2020 Mar 5;18(2):96-105. Epub 2019 Aug 5.

Menzies Health Institute Queensland, Griffith University, Brisbane, QLD, Australia.

Background: Hospital-based intravenous immunoglobulin (IVIg) treatment has been the standard treatment mode for patients with primary immunodeficiency disease (PID). With the newer home-based subcutaneous immunoglobulin (SCIg) becoming approved for use in most countries, the question arises as to whether SCIg is a cost-effective treatment mode compared to IVIg in Australia.

Materials And Methods: We developed a Markov cohort simulation model with six health states: PID without infection, PID with infection treated at home or hospital, bronchiectasis without infection, bronchiectasis with infection treated at home or hospital, bronchiectasis with chronic Pseudomonas aeruginosa infection, and death, from an Australian healthcare system perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2029.0083-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141942PMC

Blood transfusion during the COVID-19 outbreak.

Blood Transfus 2020 03;18(2):79-82

Deparment of Blood Transfusion, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0076-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141939PMC

Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.

Blood Transfus 2020 Feb 28:1-8. Epub 2020 Feb 28.

Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne.

Background: Nowadays, most blood products are leukocyte-reduced. After this procedure, the residual risk for transfusion transmitted cytomegalovirus (TT-CMV) is mostly attributed to cell-free viruses in the plasma of blood donors following primary infection or viral reactivation. Here, objectives are: 1) to study the behaviour of cell-free CMV through the blood component processing; 2) to determine the anti-CMV seroprevalence, the level of viremia, the window-period in blood donor population; and 3) to identify cases of TT-CMV in bone marrow transplant (BMT) recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0241-19DOI Listing
February 2020

The cardiovascular risk in paediatrics: the paradigm of the obstructive sleep apnoea syndrome.

Blood Transfus 2020 May 17;18(3):217-225. Epub 2020 Mar 17.

National Research Council of Italy, Institute for Research and Biomedical Innovation, Palermo, Italy.

Background: Obstructive sleep apnoea syndrome (OSAS) describes a spectrum of abnormal breathing patterns during sleep characterised by snoring, increased upper airway resistance and pharyngeal collapsibility, with alteration of normal oxygenation and ventilation. Intermittent desaturations during sleep have multi-organ implications. Adults with OSAS have an increased risk of developing a dysfunctional endothelium that is characterised by greater adherence of inflammatory mediators to endothelial cells and hypercoagulability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0283-19DOI Listing

"Valar morghulis": all red cells must die.

Blood Transfus 2020 Mar 17;18(2):83-85. Epub 2020 Mar 17.

Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Egaleo, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0028-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141935PMC

DEL.

Blood Transfus 2020 May 17;18(3):159-162. Epub 2020 Mar 17.

Red Cross Blood Service NSTOB, Institute Springe, Springe, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0296-19DOI Listing

Decoding the metabolic landscape of pathophysiological stress-induced cell death in anucleate red blood cells.

Blood Transfus 2020 Mar 28;18(2):130-142. Epub 2020 Feb 28.

Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO, USA.

Background: In response to stress, anucleate red blood cells (RBCs) can undergo a process of atypical cell death characterised by intracellular Ca accumulation and phosphatidylserine (PS) externalisation. Here we studied alterations in RBC metabolism, a critical contributor to their capacity to survive environmental challenges, during this process.

Materials And Methods: Metabolomics analyses of RBCs and supernatants, using ultra-high-pressure liquid chromatography coupled to mass spectrometry, were performed after in vitro exposure of RBCs to different pathophysiological cell stressors, including starvation, extracellular hypertonicity, hyperthermia, and supraphysiological ionic stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0256-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141938PMC

Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease.

Blood Transfus 2020 May 17;18(3):200-207. Epub 2020 Mar 17.

Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.

Background: Red blood cell (RBC) exchange (RCE) transfusion therapy is indicated for certain patients with sickle cell disease (SCD). Although beneficial, this therapy is costly and inconvenient to patients, who may require it monthly or more often. Identification of blood and plasma biomarkers that could improve or help individualise RCE therapy is of interest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0237-19DOI Listing

In search of the lost blood.

Blood Transfus 2020 01;18(1):3-5

Department of Anesthesiology and Critical Care Medicine; Englewood Hospital and Medical Center, Englewood, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0007-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053527PMC
January 2020

Blood Transfusion: interesting times ahead.

Authors:
Luca Mascaretti

Blood Transfus 2020 01;18(1):1-2

Blood Transfusion Editor-in-Chief, Azienda Sanitaria Universitaria "Giuliano Isontina" , Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2020.0033-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053525PMC
January 2020

Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.

Blood Transfus 2020 May 13;18(3):176-181. Epub 2019 Dec 13.

Rheumatology Unit, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy.

Background: The aim of this study was to evaluate the efficacy and safety of ferric carboxymaltose in rheumatic patients with iron deficiency anaemia.

Materials And Methods: The study retrospectively evaluated a cohort of 34 patients with iron deficiency anaemia affected by inflammatory rheumatic diseases that are refractory or intolerant to oral iron therapy. They were treated with ferric carboxymaltose for a total of 56 cycles of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0207-19DOI Listing

Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

Blood Transfus 2019 Nov 4:1-11. Epub 2019 Nov 4.

Regional Reference Centre for Inherited Bleeding Disorders, University Hospital of Parma, Parma, Italy.

Background: The recombinant factor VIII (rFVIII)-IgG1 Fc fusion protein (rFVIII-Fc) was the first available extended half-life rFVIII, shown to prolong dosing intervals of individualised prophylaxis in patients with severe haemophilia A, maintaining low bleeding rates and unchanged or lower FVIII dose versus standard half-life (SHL) rFVIII. Few data are available about real-world experience with rFVIII-Fc, including criteria for patient switching from SHL products, follow up and prophylaxis optimisation.

Materials And Methods: A single-centre retrospective study was designed to review patients switched to rFVIII-Fc, based on individual needs, after pharmacokinetic (PK) assessment, according to routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0220-19DOI Listing
November 2019

D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis.

Blood Transfus 2019 Nov 19:1-8. Epub 2019 Nov 19.

Department of Biomedical Sciences and Human Oncology, "Aldo Moro" University, Bari, Italy.

Background: D-dimer (DD) is the most used fibrin-related marker and has been proposed, either alone or in combination with other variables, as prognostic factor in patients with sepsis. However, DD generation depends on both coagulation and fibrinolysis, meaning that it may give false negative results in conditions associated with marked fibrinolytic inhibition such as sepsis. In this study, we tested whether correction of DD for thrombin and plasmin generation could improve its prognostic significance in septic patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0175-19DOI Listing
November 2019

Cigarette smoking and antioxidant defences in packed red blood cells prior to storage.

Blood Transfus 2020 01 20;18(1):40-48. Epub 2019 Nov 20.

Post-graduate Progamme in Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.

Background: Red blood cells from smoking donors can have more lesions from oxidative stress, decreasing the benefits of blood transfusion. We aimed to explore the effect of cigarette smoking on the oxidative status of packed red blood cells (PRBCs) prior to storage.

Materials And Methods: We compared serum vitamin C, plasmatic malondialdehyde (MDA), and non-protein thiol groups (GSH) levels in PRBCs, as well glutathione peroxidase (GPx) and glutathione s-transferase (GST) activity in PRBCs from smoking (n=36) and non-smoking (n=36) donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0166-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053519PMC
January 2020

Perioperative blood loss: estimation of blood volume loss or haemoglobin mass loss?

Blood Transfus 2020 01 27;18(1):20-29. Epub 2019 Nov 27.

Department of Anaesthesiology, "CLINIC de Barcelona" Hospital, Barcelona, Spain.

Background: Perioperative blood loss is an essential parameter in research into Patient Blood Management. However, currently there is no "gold standard" method to quantify it. Direct measurements of blood loss are considered unreliable methods, and the formulae to estimate it have proven to be significantly inaccurate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0204-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053522PMC
January 2020

Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs.

Blood Transfus 2020 Mar 17;18(2):106-116. Epub 2019 Dec 17.

Blood Transfusion Centre, Legnano General Hospital, Legnano, Italy.

Background: Moderate to severe iron deficiency anaemia is a common finding in patients admitted to the Emergency Department (ED). According to Patient Blood Management principles, intravenous iron should be the therapy of choice instead of blood transfusion for selected cases affected by chronic iron deficiency anaemia. However, this option is only rarely taken into account by physicians in the ED. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0248-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141934PMC

Factor VIII replacement is still the standard of care in haemophilia A.

Blood Transfus 2019 11 11;17(6):479-486. Epub 2019 Dec 11.

University of Illinois College of Medicine, and the Bleeding and Clotting Disorders Institute, Peoria, IL, United States of America.

Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients' quality of life and increase therapeutic adherence. New licensed classes of non-replacement products include prophylactic emicizumab, which is administered subcutaneously up to every 4 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0211-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917528PMC
November 2019

Platelet-rich plasma for sports-related muscle, tendon and ligament injuries: an umbrella review.

Blood Transfus 2019 11 11;17(6):465-478. Epub 2019 Dec 11.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: Platelet-rich plasma (PRP) has been used in different non-transfusion indications due to its role in tissue regeneration and healing. The aim of this overview of systematic reviews (umbrella review) is to provide a summary of the existing research syntheses related to PRP use for sports-related muscle, tendon and ligament injuries.

Materials And Methods: Literature searches were performed in MEDLINE, Embase, and Cochrane Library to identify systematic reviews focusing on PRP use for sports-related muscle, tendon and ligament injuries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0274-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917536PMC
November 2019
2.372 Impact Factor

The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative.

Blood Transfus 2019 11 11;17(6):449-458. Epub 2019 Dec 11.

Italian National Blood Transfusion Centre, Rome, Italy.

Since the inception of industrial plasma fractionation during the Second World War, a succession of protein therapies isolated from plasma have determined the volume of plasma requiring collection, and have also shaped the economics of the industry. These so-called plasma drivers have successively included albumin, coagulation Factor VIII (FVIII) and, for the past thirty years, intravenously (IV) and subcutaneously (SC) administered immunoglobulin (IG) solutions. The sale of IG underpins the profitability of the industry and has experienced continuous growth over the past decades, as the result of growing clinical demand. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0265-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917530PMC
November 2019
2.372 Impact Factor

Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

Blood Transfus 2019 11 11;17(6):433-448. Epub 2019 Dec 11.

IRCCS Foundation Ca' Granda Maggiore Policlinico Hospital, Milan, Italy.

Pathogen reduction (PR) of selected blood components is a technology that has been adopted in practice in various ways. Although they offer great advantages in improving the safety of the blood supply, these technologies have limitations which hinder their broader use, e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0288-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917531PMC
November 2019

Hepatitis E virus infection prevalence among men who have sex with men involved in a hepatitis A virus outbreak in Italy.

Blood Transfus 2019 11;17(6):428-432

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Background: The routes of hepatitis E virus (HEV) transmission have still not been fully clarified. Here, we evaluated the possibility of sexual transmission of HEV, which remains a highly disputed issue.

Materials And Methods: Hepatitis E virus sexual transmission risk was assessed by comparing the prevalence of HEV infection in a sample of 196 Italian men who have sex with men (MSM) involved in a multi-country hepatitis A virus (HAV) outbreak, and in 3,912 Italian male blood donors selected from the same regions and provinces as the MSM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0209-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917535PMC
November 2019

Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018.

Blood Transfus 2019 11 11;17(6):409-417. Epub 2019 Dec 11.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: In Italy, the use of nucleic acid testing for hepatitis B virus (HBV) in donor screening has allowed the detection of infections in the window phase, as well as the presence of occult infections which could potentially be transmitted. The aim of this study was to analyse the trends of epidemiological data focused on HBV infection in blood donors and to estimate the residual risk of transmitting HBV from both the window phase and occult infection over a 10-year period in Italy.

Materials And Methods: Data were obtained from the Italian Haemovigilance System which includes the results of screening tests for transfusion transmissible infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0245-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917538PMC
November 2019
2.372 Impact Factor

Occult hepatitis B infection among blood donors from Yaoundé, Cameroon.

Blood Transfus 2019 11;17(6):403-408

National Institute of Blood Transfusion/INTS, Department of Blood Borne Agents, National Reference Center for Infectious Risks in Blood Transfusion, Paris, France.

Background: In Cameroon, the prevention of hepatitis B virus (HBV) transmission by blood transfusion is still only based on hepatitis B surface antigen (HBsAg) screening. However, occult HBV infection (OBI) characterised by the absence of detectable HBsAg and low level of viral DNA remains a potential threat for blood safety. The prevalence of OBI was investigated in blood donors from Yaoundé to provide evidence-based recommendations to improve HBV blood safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0182-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917532PMC
November 2019
2.372 Impact Factor

"The times they are a-changin", ... or maybe not?

Blood Transfus 2019 11 11;17(6):401-402. Epub 2019 Dec 11.

Italian National Blood Centre, National Institute of Health, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0259-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917533PMC
November 2019

Uncovering occult hepatitis B in blood donations: a tale of two worlds.

Blood Transfus 2019 11 11;17(6):399-400. Epub 2019 Dec 11.

Department of Transfusion Medicine and Haematology, "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico", Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0302-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917529PMC
November 2019

In vitro evidence supporting applications of platelet derivatives in regenerative medicine.

Blood Transfus 2020 Mar 8;18(2):117-129. Epub 2019 Oct 8.

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

The role of platelets in haemostasis has long been known, but understanding of these cells' involvement in wound healing/tissue repair is more recent and has given rise to a multitude of translational studies. Tissue repair processes consist of complex, regulated interactions between cells modulated by biologically active molecules, most of which are growth factors released by activated platelets: this aspect represents the rationale on which the use of platelet derivatives for clinical purposes is based. In the last years, many in vitro studies have focused on the mechanisms of action by which these growth factors affect the biological activities of cells, thus supporting tissue healing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0164-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141937PMC

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

Blood Transfus 2020 Mar 18;18(2):143-151. Epub 2019 Oct 18.

Haemophilia Centre, Department of Medicine, University Hospital of Padua, Padua, Italy.

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0186-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141940PMC
March 2020
3 Reads

Occult hepatitis B infection among blood donors from Yaoundé, Cameroon.

Blood Transfus 2019 Sep 24:1-6. Epub 2019 Sep 24.

National Institute of Blood Transfusion/INTS, Department of Blood Borne Agents, National Reference Center for Infectious Risks in Blood Transfusion, Paris, France.

Background: In Cameroon, the prevention of hepatitis B virus (HBV) transmission by blood transfusion is still only based on hepatitis B surface antigen (HBsAg) screening. However, occult HBV infection (OBI) characterised by the absence of detectable HBsAg and low level of viral DNA remains a potential threat for blood safety. The prevalence of OBI was investigated in blood donors from Yaoundé to provide evidence-based recommendations to improve HBV blood safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.00182-19DOI Listing
September 2019
6 Reads
2.372 Impact Factor

Lifestyle behaviours are not associated with haemolysis: results from Donor InSight.

Blood Transfus 2020 Mar 21;18(2):86-95. Epub 2019 Oct 21.

Department of Donor Medicine Research-Donor Studies, Sanquin Research, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.

Background: Lifestyle behaviours such as physical activity, sedentary behaviour and dietary habits have been shown to influence blood lipid levels, and both lifestyle and blood lipids may be associated with haemolysis during storage of blood products. We aimed to investigate whether lifestyle behaviours are associated with degree of haemolysis in red cell concentrates (RCC), and if such associations are mediated by low-density lipoprotein (LDL) cholesterol and triglyceride levels.

Materials And Methods: Cross-sectional analyses were performed in data from 760 Dutch blood donors participating in Donor InSight, an observational cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0151-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141933PMC

Hepatitis E virus infection prevalence among men who have sex with men involved in a hepatitis A virus outbreak in Italy.

Blood Transfus 2019 Oct 8:1-5. Epub 2019 Oct 8.

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

Background: The routes of hepatitis E virus (HEV) transmission have still not been fully clarified. Here, we evaluated the possibility of sexual transmission of HEV, which remains a highly disputed issue.

Materials And Methods: Hepatitis E virus sexual transmission risk was assessed by comparing the prevalence of HEV infection in a sample of 196 Italian men who have sex with men (MSM) involved in a multi-country hepatitis A virus (HAV) outbreak, and in 3,912 Italian male blood donors selected from the same regions and provinces as the MSM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.020919DOI Listing
October 2019

Pulmonary embolism associated with transfusion after severe post-partum haemorrhage: is less more?

Blood Transfus 2020 01 12;18(1):13-19. Epub 2019 Sep 12.

Immunohaematology and Transfusion Medicine Service, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy.

Background: Transfusion of red blood cells is associated with superficial vein thrombosis (SVT) and venous thromboembolism (deep vein thrombosis and/or pulmonary embolism, VTE). The present study investigated the prevalence of SVT and VTE in women transfused in the peri-partum period.

Materials And Methods: We carried out an observational study in a tertiary level obstetrics department in the Apulia Region of Southern Italy to investigate VTE in women transfused during or after labour. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0060-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053526PMC
January 2020

The use of platelet-rich plasma in oral surgery: a systematic review and meta-analysis.

Blood Transfus 2019 09;17(5):357-367

Italian National Blood Centre, National Institute of Health, Rome, Italy.

Background: The aim of this systematic review and meta-analysis was to evaluate the benefit of platelet rich plasma (PRP) in oral surgery.

Materials And Methods: We performed a systematic search of the literature. The GRADE system was used to assess the certainty of the body of evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0177-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774927PMC
September 2019
1 Read
2.372 Impact Factor

Assessment of haematopoietic progenitor cell counting with the Sysmex XN-1000 to guide timing of apheresis of peripheral blood stem cells.

Blood Transfus 2020 01 25;18(1):67-76. Epub 2019 Jul 25.

Section of Clinical Biochemistry, Department of Medicine, University of Verona, Verona, Italy.

Background: Successful peripheral blood stem cell (PBSC) collection depends on optimal timing of apheresis, as usually determined by flow cytometry CD34-positive () cell count in peripheral blood (PB). Since this method is costly and labour-intensive, we evaluated the use of the Hematopoietic Progenitor Cell count programme on a Sysmex XN haematologic analyser (XN-HPC) as a rapid and inexpensive alternative for predicting CD34 cell count in PB samples.

Materials And Methods: Haematopoietic progenitor cell and CD34 cell counts were compared using 273 PB samples collected from 78 healthy donors and 72 patients who underwent PBSC transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0086-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053521PMC
January 2020
17 Reads

Haemostatic responsiveness and release of biological response modifiers following cryopreservation of platelets treated with amotosalen and ultraviolet A light.

Blood Transfus 2020 May 4;18(3):191-199. Epub 2019 Jul 4.

Department of Clinical Immunology and Transfusion Medicine (KITM), Intervention and Technology (CLINTEC), Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

Background: Due to the risk of replication of contaminating pathogens, platelets have a limited storage time of 5 days, which can be prolonged to 7 days by the use of pathogen inactivation technologies. Cryopreservation (CP) may be an alternative to permit longer storage periods and increased availability. However, the preparation of platelets can result in secretion of biological response modifiers (BRM), which can cause adverse transfusion reactions in the recipient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0061-19DOI Listing
May 2020
3 Reads

Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.

Blood Transfus 2019 Aug 5:1-10. Epub 2019 Aug 5.

Menzies Health Institute Queensland, Griffith University, Brisbane, Australia.

Background: Hospital-based intravenous immunoglobulin (IVIg) treatment has been the standard treatment mode for patients with primary immunodeficiency disease (PID). With the newer home-based subcutaneous immunoglobulin (SCIg) becoming approved for use in most countries, the question arises as to whether SCIg is a cost-effective treatment mode compared to IVIg in Australia.

Materials And Methods: We developed a Markov cohort simulation model with six health states: PID without infection, PID with infection treated at home or hospital, bronchiectasis without infection, bronchiectasis with infection treated at home or hospital, bronchiectasis with chronic Pseudomonas aeruginosa infection, and death, from an Australian healthcare system perspective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0083-19DOI Listing
August 2019
2 Reads

Patient Blood Management: transfusion appropriateness in the post-operative period.

Blood Transfus 2019 11;17(6):459-464

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Background: Within the context of Patient Blood Management (PBM) policy for the peri-operative period, the transfusion medicine unit of our institution adopted a series of strategies to support and enhance red blood cell (RBC) transfusion best practices. This study aimed to evaluate the appropriateness of RBC transfusion therapy in the post-operative period, before and after starting a multifactorial PBM policy.

Materials And Methods: A 2-phase observational study was conducted on patients who underwent major surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0035-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917537PMC
November 2019
4 Reads

Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003-2017).

Blood Transfus 2019 11;17(6):418-427

Blood Transfusion Centre of the Valencian Community, Valencia, Spain.

Background: Towards the end of the 20 century, transfusion-transmitted viral infections (TTVI) represented a huge problem for public health. From the beginning of the screening of blood donations, this risk has decreased to the point that it is no longer possible to measure it directly and it is necessary to use mathematical models. Using one of these models, the aim of this study was to analyse the evolution of the residual risk of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) transmission through blood transfusion from 2003 to 2017 in the Region of Valencia, Spain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2019.0058-19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917534PMC
November 2019
4 Reads